These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30231128)

  • 1. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis.
    Marques VD; Passos GRD; Mendes MF; Callegaro D; Lana-Peixoto MA; Comini-Frota ER; Vasconcelos CCF; Sato DK; Ferreira MLB; Parolin MKF; Damasceno A; Grzesiuk AK; Muniz A; Matta APDC; Oliveira BES; Tauil CB; Maciel DRK; Diniz DS; Corrêa EC; Coronetti F; Jorge FMH; Sato HK; Gonçalves MVM; Sousa NAC; Nascimento OJM; Gama PDD; Domingues R; Simm RF; Thomaz RB; Morales RR; Dias RM; Apóstolos-Pereira SD; Machado SCN; Junqueira TF; Becker J
    Arq Neuropsiquiatr; 2018 Aug; 76(8):539-554. PubMed ID: 30231128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology.
    Comini-Frota ER; Vasconcelos CC; Mendes MF
    Arq Neuropsiquiatr; 2017 Jan; 75(1):57-65. PubMed ID: 28099564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology.
    Brum DG; Comini-Frota ER; Vasconcelos CC; Dias-Tosta E
    Arq Neuropsiquiatr; 2014 Feb; 72(2):152-6. PubMed ID: 24604370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for the treatment of multiple sclerosis with immunomodulatory drugs].
    Academia Brasileira de Neurologia. Departamento Científico de Neuroimunologia
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):892-5. PubMed ID: 16258680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Laurson-Doube J; Rijke N; Helme A; Baneke P; Banwell B; Viswanathan S; Hemmer B; Yamout B
    Mult Scler; 2021 Aug; 27(9):1403-1410. PubMed ID: 34304636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait.
    Alroughani R; Ashkanani A; Al-Hashel J; Khan R; Thussu A; Alexander KJ; Vembu P; Sharfuddin K; Lamdhade S; John JK; Alkhashan S; Abualmelh M; Al-Shammri S
    Clin Neurol Neurosurg; 2016 Apr; 143():51-64. PubMed ID: 26896783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis.
    Marin CE; Callegaro D; Lana-Peixoto MA; Fernández O; Gomes Neto AP; Vasconcelos CCF; d'Almeida JAC; Gonçalves MVM; Mendes MF; Parolin MKF; Nascimento O; Gama PDD; Dias-Carneiro RPC; Dias RM; Damasceno A; Becker J
    Arq Neuropsiquiatr; 2021 Jul; 79(7):598-606. PubMed ID: 34468497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: no.
    Weinshenker BG
    Mult Scler; 2012 Sep; 18(9):1211-2. PubMed ID: 22936683
    [No Abstract]   [Full Text] [Related]  

  • 10. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
    Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: commentary.
    Hutchinson M
    Mult Scler; 2012 Sep; 18(9):1213-4. PubMed ID: 22936684
    [No Abstract]   [Full Text] [Related]  

  • 12. World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    McDonell J; Costello K; Laurson-Doube J; Rijke N; Giovannoni G; Banwell B; Baneke P
    Mult Scler; 2020 Feb; 26(2):153-158. PubMed ID: 31944872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system.
    Becker J; Ferreira LC; Damasceno A; Bichuetti DB; Christo PP; Callegaro D; Peixoto MAL; Sousa NAC; Almeida SM; Adoni T; Santiago-Amaral J; Junqueira T; Pereira SLA; Gomes ABAGR; Pitombeira M; Paolilo RB; Grzesiuk AK; Piccolo AC; D Almeida JAC; Gomes Neto AP; Oliveira ACP; Oliveira BS; Tauil CB; Vasconcelos CF; Kaimen-Maciel D; Varela D; Diniz DS; Oliveira EML; Malfetano FR; Borges FE; Figueira FFA; Gondim FAA; Passos GRD; Silva GD; Olival GSD; Santos GACD; Ruocco HH; Sato HK; Soares Neto HR; Cortoni Calia L; Gonçalves MVM; Vecino MCA; Pimentel MLV; Ribeiro MC; Boaventura M; Parolin MKF; Melo RBS; Lázaro R; Thomaz RB; Kleinpaul R; Dias RM; Gomes S; Lucatto SA; Alves-Leon SV; Fukuda T; Ribeiro TAGJ; Winckler TCD; Fragoso YD; Nascimento OJMD; Ferreira MLB; Mendes MF; Brum DG; Glehn FV
    Arq Neuropsiquiatr; 2021 Nov; 79(11):1049-1061. PubMed ID: 34816999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: yes.
    Havrdová E
    Mult Scler; 2012 Sep; 18(9):1209-10. PubMed ID: 22936682
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.
    Corboy JR; Weinshenker BG; Wingerchuk DM
    Neurology; 2018 Jun; 90(24):1106-1112. PubMed ID: 29685920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms.
    Saba RA; Maia DP; Cardoso FEC; Borges V; F Andrade LA; Ferraz HB; Barbosa ER; Rieder CRM; da Silva DJ; Chien HF; Capato T; Rosso AL; Souza Lima CF; Bezerra JMF; Nicaretta D; Povoas Barsottini OG; Godeiro-Júnior C; Broseghini Barcelos L; Cury RG; Spitz M; Azevedo Silva SMC; Della Colletta MV
    Arq Neuropsiquiatr; 2022 Mar; 80(3):316-329. PubMed ID: 35319667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1857-65. PubMed ID: 24993136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cannabinoids in neurology--Brazilian Academy of Neurology].
    Brucki SM; Frota NA; Schestatsky P; Souza AH; Carvalho VN; Manreza ML; Mendes MF; Comini-Frota E; Vasconcelos C; Tumas V; Ferraz HB; Barbosa E; Jurno ME
    Arq Neuropsiquiatr; 2015 Apr; 73(4):371-4. PubMed ID: 25992535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients.
    Rostami Mansoor S; Ghasemi-Kasman M
    J Med Virol; 2021 Mar; 93(3):1314-1319. PubMed ID: 33044760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.